Citigroup
TRVI icon

Citigroup’s Trevi Therapeutics TRVI Stock Holding History

Citigroup’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Sell
99,949
-23,549
-19% -$264K ﹤0.01% 2999
2025
Q4 		$1.55M Buy
123,498
+96,585
+359% +$1.12M ﹤0.01% 2825
2025
Q3 		$246K Sell
26,913
-37,046
-58% -$278K ﹤0.01% 3909
2025
Q2 		$350K Buy
63,959
+10,065
+19% +$62.6K ﹤0.01% 3820
2025
Q1 		$339K Buy
53,894
+6,038
+13% +$28.8K ﹤0.01% 3886
2024
Q4 		$197K Buy
47,856
+5,232
+12% +$16.7K ﹤0.01% 4421
2024
Q3 		$142K Buy
42,624
+29,637
+228% +$88.1K ﹤0.01% 4585
2024
Q2 		$38.7K Buy
12,987
+4,284
+49% +$11.9K ﹤0.01% 4724
2024
Q1 		$30K Buy
8,703
+1,747
+25% +$3.9K ﹤0.01% 4892
2023
Q4 		$9.32K Buy
6,956
+6,913
+16,077% +$10.5K ﹤0.01% 5206
2023
Q3 		$94 Sell
43
-12,355
-100% -$27.9K ﹤0.01% 5422
2023
Q2 		$29.6K Buy
+12,398
New +$31.2K ﹤0.01% 4852
2022
Q3 		– Sell
-1,700
Closed -$5K – 6325
2022
Q2 		$5K Buy
+1,700
New +$4.18K ﹤0.01% 5633

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Citigroup's TRVI Position: Q1 2026 in Review

Citigroup reduced its Trevi Therapeutics (TRVI) stake by 19% in Q1 2026, selling an estimated $264K and leaving 99,949 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Citigroup first reported a position in TRVI in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.55M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Citigroup held 99,949 shares of Trevi Therapeutics worth $1.19M as of Q1 2026.
  • Citigroup sold 23,549 Trevi Therapeutics shares in Q1 2026, an estimated $264K.
  • Trevi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2999 holding.
  • Citigroup first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Citigroup's Trevi Therapeutics position peaked at $1.55M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.